SCHEMBL344818

SCHEMBL344818

CC(N)CCNCCCCN

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.56
CA2 P00918 3/20 0.56
CA4 P22748 3/20 0.56
CA6 P23280 3/20 0.56
CA5A P35218 3/20 0.56
CA7 P43166 3/20 0.56
CA9 Q16790 3/20 0.56
CA14 Q9ULX7 3/20 0.56
CA5B Q9Y2D0 3/20 0.56
F13A1 P00488 2/20 0.56
CYP1A2 P05177 2/20 0.56
ALOX15 P16050 2/20 0.56
THPO P40225 2/20 0.56
CA3 P07451 2/20 0.56
CA1 P00915 1/20 0.56
CYP2C9 P11712 1/20 0.56
PKM P14618 1/20 0.56
TSHR P16473 1/20 0.56
MTOR P42345 1/20 0.56
LMNA P02545 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14519033 1.00 CA12 (0.56) CA12CA2CA4CA6CA5A
SCHEMBL5810196 1.00 CA12 (0.56) CA12CA2CA4CA6CA5A
SCHEMBL14163247 0.98 CA12 (0.54) CA12CA2CA4CA6CA5A
SCHEMBL12227390 0.98 CA12 (0.54) CA12CA2CA4CA6CA5A
SCHEMBL14360554 0.95 CA12 (0.59) CA12CA2CA4CA6CA5A
SCHEMBL343049 0.95 CA12 (0.59) CA12CA2CA4CA6CA5A
SCHEMBL5565820 0.93 CA12 (0.56) CA12CA2CA4CA6CA5A
SCHEMBL6030226 0.93 CA12 (0.56) CA12CA2CA4CA6CA5A
SCHEMBL6030318 0.93 CA12 (0.56) CA12CA2CA4CA6CA5A
SCHEMBL5196477 0.93 CA12 (0.55) CA12CA2CA4CA6CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202280-B2 Methods for the treatment and prevention of pancreatitis and for induction of liver regeneration RAESAENEN TIINA-LIISA 2007-04-10 US claimed
EP-1049444-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2004-03-24 EP claimed
EP-1049444-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-11-08 EP claimed
US-6060471-A Reduction of hair growth VLSI TECHNOLOGY, INC. 2000-05-09 US claimed
WO-1999037277-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 1999-07-29 WO claimed
CN-108135933-B Motile sperm domain containing protein 2 and cancer 脉管生物生长有限公司 2022-04-29 CN disclosed
CN-107921084-B Motile sperm domain containing protein 2 and inflammation 脉管生物生长有限公司 2022-04-29 CN disclosed
US-20210030703-A1 USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2021-02-04 US disclosed
EP-3765085-A1 USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS Université de Paris (FR) 2021-01-20 EP disclosed
CN-112218658-A Use of caloric restriction mimetics for enhancing chemoimmunotherapy for cancer treatment 国家健康科学研究所 2021-01-12 CN disclosed
US-10617656-B2 Methods of increasing the cytotoxicity of chemotherapeutic agents with multisubstrate inhibitors of histone, protein-Lys, polyamine acetylation, and polyamine metabolism VANDERBILT UNIVERSITY (US) 2020-04-14 US disclosed
WO-2019175113-A1 USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2019-09-19 WO disclosed
US-20040180968-A1 Methods for the treatment and prevention of pancreatitis and for induction of liver regeneration RASANEN TIINA-LIISA (FI) 2004-09-16 US disclosed
JP-2004189714-A MEDICINE FOR TREATING AND PREVENTING PANCREATITIS AND INDUCING HEPATIC REGENERATIVE FUNCTION TIINA-LIISA RASANEN 2004-07-08 JP disclosed
EP-1049444-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2004-03-24 EP disclosed
EP-1049444-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-11-08 EP disclosed
US-6060471-A Reduction of hair growth VLSI TECHNOLOGY, INC. 2000-05-09 US disclosed
WO-1999037277-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 1999-07-29 WO disclosed
US-5344846-A Administering aminoalkylguanidine; antitumor agents THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1994-09-06 US disclosed
WO-1994015596-A1 COMPOSITIONS AND METHODS FOR INHIBITING DEOXYHYPUSINE SYNTHASE AND THE GROWTH OF CELLS THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1994-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210030703-A1 USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS CD274, PDCD1, PDCD10 CA12 2812/4885CA2 2395/4885CA4 730/4885
US-20040180968-A1 Methods for the treatment and prevention of pancreatitis and for induction of liver regeneration SRM, SMOX, SMS CA12 3648/4885CA2 4084/4885CA4 3959/4885
US-10617656-B2 Methods of increasing the cytotoxicity of chemotherapeutic agents with multisubstrate inhibitors of histone, protein-Lys, polyamine acetylation, and polyamine metabolism KAT2A, HDAC1, HDAC10 CA12 1923/4885CA2 991/4885CA4 1709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.